HCPCS Level II · Drugs administered other than oral method
J3245Injection, tildrakizumab, 1 mg
✓ Active
Source: CMS HCPCS quarterly update, October 2026. Page updated September 29, 2026.
About J3245
J3245 is an HCPCS Level II code in the J series (drugs administered other than oral method), describing injection, tildrakizumab, 1 mg.
It was added to HCPCS effective 01/01/2019.
Its Medicare coverage code is "C", meaning coverage is left to the Medicare contractor's judgment.
Details
- Short description
- Inj., tildrakizumab, 1 mg
- Date added
- 01/01/2019
- Action effective
- 01/01/2019
- BETOS
- O1E
Related J32xx codes
- J3230Injection, chlorpromazine hcl, up to 50 mg
- J3240Injection, thyrotropin alpha, 0.9 mg, provided in 1.1 mg vial
- J3241Injection, teprotumumab-trbw, 10 mg
- J3243Injection, tigecycline, 1 mg
- J3244Injection, tigecycline (accord), not therapeutically equivalent to j3243, 1 mg
- J3246Injection, tirofiban hcl, 0.25 mg
- J3247Injection, secukinumab, intravenous, 1 mg
- J3250Injection, trimethobenzamide hcl, up to 200 mg
- J3260Injection, tobramycin sulfate, up to 80 mg
- J3262Injection, tocilizumab, 1 mg
- J3263Injection, toripalimab-tpzi, 1 mg
- J3265Injection, torsemide, 10 mg/ml
Common questions about J3245
Is HCPCS J3245 still valid?
- Yes. J3245 is active in the CMS October 2026 HCPCS file.
Does Medicare cover J3245?
- Its coverage code is "C": coverage is left to the Medicare contractor's judgment. Check the local coverage determination for your region.